
|Videos|April 26, 2016
Meredith Buxton Discusses the I-SPY 2 Trial
Author(s)Meredith Buxton, PhD
Meredith Buxton, PhD, University of California San Francisco, discusses the I-SPY 2 trial, for which she is the executive director.
Advertisement
Meredith Buxton, PhD, University of California San Francisco, discusses the I-SPY 2 trial, for which she is the executive director.
The goal of I-SPY 2 is to test new agents, like immunotherapies, and ultimately get them to patients sooner. While it is currently only being used in the breast cancer domain, Buxton noted that hopefully other cancer types will also join in the trial.
Advertisement
Related Content
Advertisement




First-Line Treatment Choice and Altering Resistance in EGFR-Mutant NSCLC
Published: | Updated:

Latest CME
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Zanidatamab-hrii in GEA: Key Takeaways for Oncology Nurses
2
Managing Daraxonrasib: Key Takeaways and Efficacy Insights for Oncology Nurses
3
Addressing Financial Toxicity: Team-Based Workflows in Oncology Care
4
Early Amivantamab Experience and Subcutaneous Dosing in COPERNICUS
5












































